Summary (tl;dr)

The Trump administration has announced it will end a Medicare Part D subsidy program after the 2026 plan year, which is expected to impact prescription drug premiums for millions of beneficiaries starting in 2027.

Essential Background

Medicare Part D provides outpatient prescription drug coverage, primarily offered through private insurance companies approved by the federal government. The Inflation Reduction Act (IRA), introduced in 2022, brought about significant changes to Medicare Part D, including capping out-of-pocket prescription drug costs and expanding eligibility for the Low-Income Subsidy (LIS) program, also known as "Extra Help." To help stabilize premiums and enrollment amidst these changes, particularly those shifting more costs onto Part D insurers, the Biden administration initiated the Part D Premium Stabilization Demonstration in 2025. This demonstration provided federal subsidies to insurers to help keep monthly premiums for stand-alone prescription drug plans lower.

The Full Story

On July 29, 2026, the Centers for Medicare & Medicaid Services (CMS), operating under the Trump administration, announced its decision to terminate the Part D Premium Stabilization Demonstration at the close of the 2026 plan year. CMS Administrator Mehmet Oz stated on social media that the program, which he characterized as providing "billions of taxpayer money" to insurance companies, was no longer necessary as the market had stabilized. The administration asserts that most Medicare recipients will see premiums rise by $10 or less, with some potentially experiencing lower premiums, as the market is deemed capable of operating under "traditional market conditions." However, the discontinuation of the subsidy, which cost the government $3.6 billion in 2026, could lead to larger premium increases for some Part D stand-alone drug plan enrollees in 2027. Final details on 2027 Medicare Advantage and Part D premiums are expected to be released in September.

Why It Matters

This decision is trending because it directly affects the financial burden of prescription drugs for approximately 25 million Americans who use stand-alone Medicare Part D plans and another 31 million who get drug coverage through Medicare Advantage. While the administration claims the impact on premiums will be minimal for most, some beneficiaries may face increased out-of-pocket costs for their medications, potentially making prescription drugs less affordable for those with limited incomes. The change also represents a shift in federal policy regarding direct support for drug plan premiums, prompting concern and interest among current and prospective Medicare beneficiaries and their families.

Geographic Location

• Washington, D.C., United States (announcement by Centers for Medicare & Medicaid Services to end Part D Premium Stabilization Demonstration)